The perpetrator potential of sitaxentan based on its ability to inhibit human cytochrome P450 (CYP) enzymes Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
Association analysis between polymorphisms in the cytochrome P450 2J2, 2S1 and UDP-glucuronosyltransferase 2B7 genes with occupational chronic bronchitis Source: Annual Congress 2010 - Genetics of obstruction Year: 2010
Cytochrome P450 1A1 polymorphism and severity of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002
Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge Source: Eur Respir J 2010; 36: 1088-1098 Year: 2010
Effects of aryl hydrocarbon receptor and cytochrome P450 1A1 polymorphisms on childhood lung function and asthma Source: Eur Respir J 2007; 30: Suppl. 51, 296s Year: 2007
Absence of inhibitory effect of levocetirizine on the metabolism of human cytochrome P450 model substrates Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
The victim potential of sitaxentan: metabolism by human CYP450 enzymes Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
Genetic polymorphisms in the cytochromes P450, microsomal epoxide hydrolase and glutathione S-transferase M1, T1 and P1 genes and their relationship to relapsing bronchitis and pneumonia in case of children Source: Eur Respir J 2005; 26: Suppl. 49, 167s Year: 2005
Cytochrome P450 2A5 methylation and gene expression profile is organ-specific and affected by maternal smoking during pregnancy Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018
The perpetrator potential of sitaxentan: human CYP enzyme induction Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
Cytochrome P450 pharmacogenetics: a possible predictor of pulmonary drug induced toxicity? Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007
Interactions between roflumilast and cytochrome P450 inducers and inhibitors: Overview of existing studies Source: Annual Congress 2010 - Management of airway disease Year: 2010
Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD Source: Eur Respir J 2008; 32: 931-937 Year: 2008
Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer Source: Eur Respir J 2010; 35: 152-159 Year: 2010
Interaction of GSTMI null variant and cytochrome P-450 type 1A1 Ile462Val polymorphism and susceptibility to COPD Source: Eur Respir J 2002; 20: Suppl. 38, 94s Year: 2002
Common variants of the microsomal epoxide hydrolase and glutamate-cysteine ligase in European populations are not associated with susceptibility to COPD Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008
Polymorphisms for epoxide hydrolase, glutathione transferase and genetic susceptibility to COPD Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Effect of genetic polymorphisms of some cytokines and xenobiotic-metabolizing enzymes on the lung function in patients with COPD Source: Annual Congress 2012 - Recent progress in mechanisms and diagnostics of COPD and asthma Year: 2012
Association of polymorphisms of cytochrome P450 genes (CYP1A1 and CYP1A2 ) with chronic obstructive pulmonary disease in Tatars and Russians from Bashkortostan Source: Eur Respir J 2007; 30: Suppl. 51, 21s Year: 2007
Cytochrome CYP2C9 and vitamin K epoxide reductase gene polymorphisms in patients with pulmonary embolism treated with warfarin Source: Annual Congress 2007 - The role of gene polymorphisms in pulmonary disease susceptibility Year: 2007